See more : 79North Inc. (JQ.CN) Income Statement Analysis – Financial Results
Complete financial analysis of Neurocrine Biosciences, Inc. (NBIX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Neurocrine Biosciences, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Ebro Foods, S.A. (EBRPY) Income Statement Analysis – Financial Results
- ZJLD Group Inc (6979.HK) Income Statement Analysis – Financial Results
- The Necessity Retail REIT, Inc. (RTLPP) Income Statement Analysis – Financial Results
- Lincoln Ventures Ltd. (TEKXF) Income Statement Analysis – Financial Results
- Ouster, Inc. (OUST) Income Statement Analysis – Financial Results
Neurocrine Biosciences, Inc. (NBIX)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.neurocrine.com
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.89B | 1.49B | 1.13B | 1.05B | 788.10M | 451.24M | 161.63M | 15.00M | 19.77M | 0.00 | 2.92M | 53.14M | 77.41M | 33.50M | 2.95M | 3.98M | 1.22M | 39.23M | 123.89M | 85.18M | 139.08M | 18.05M | 41.24M | 14.59M | 16.80M | 16.00M | 26.10M | 19.20M |
| Cost of Revenue | 39.70M | 23.20M | 14.30M | 10.10M | 7.40M | 4.89M | 1.25M | 35.90M | 33.80M | 14.40M | 13.80M | 11.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -2.20M | -2.10M | -1.70M | -1.30M | -1.00M |
| Gross Profit | 1.85B | 1.47B | 1.12B | 1.04B | 780.70M | 446.35M | 160.37M | -20.90M | -14.03M | -14.40M | -10.88M | 41.54M | 77.41M | 33.50M | 2.95M | 3.98M | 1.22M | 39.23M | 123.89M | 85.18M | 139.08M | 18.05M | 41.24M | 16.79M | 18.90M | 17.70M | 27.40M | 20.20M |
| Gross Profit Ratio | 97.90% | 98.44% | 98.74% | 99.03% | 99.06% | 98.92% | 99.22% | -139.33% | -70.97% | 0.00% | -372.76% | 78.17% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 115.07% | 112.50% | 110.63% | 104.98% | 105.21% |
| Research & Development | 565.00M | 463.80M | 328.10M | 275.00M | 200.00M | 160.52M | 121.83M | 94.29M | 81.49M | 46.43M | 39.25M | 37.16M | 30.95M | 31.15M | 35.81M | 55.29M | 81.99M | 97.68M | 106.63M | 115.07M | 177.27M | 108.94M | 74.27M | 40.23M | 29.20M | 21.80M | 19.90M | 12.60M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 248.93M | 169.91M | 68.08M | 32.48M | 17.99M | 13.35M | 13.44M | 12.54M | 16.07M | 14.83M | 20.24M | 37.48M | 54.87M | 42.33M | 22.44M | 20.59M | 12.72M | 10.86M | 9.96M | 7.50M | 6.60M | 5.70M | 3.70M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -82.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 887.60M | 752.70M | 583.30M | 433.30M | 354.10M | 248.93M | 169.91M | 68.08M | 32.48M | 17.99M | 13.35M | 13.44M | 12.46M | 16.07M | 14.83M | 20.24M | 37.48M | 54.87M | 42.33M | 22.44M | 20.59M | 12.72M | 10.86M | 9.96M | 7.50M | 6.60M | 5.70M | 3.70M |
| Other Expenses | 143.90M | 0.00 | 105.30M | 164.50M | 154.27M | 0.00 | -20.00K | 13.00K | 11.00K | 18.00K | 16.00K | 14.00K | 42.23M | 73.29M | 70.99M | 15.74M | 94.00M | 90.96M | 97.44M | 87.91M | 80.57M | 96.58M | 0.00 | 2.20M | 2.10M | 1.70M | 1.30M | 1.00M |
| Operating Expenses | 1.60B | 1.22B | 911.40M | 708.30M | 554.10M | 409.46M | 291.73M | 162.37M | 113.97M | 64.41M | 52.60M | 51.69M | 43.41M | 47.22M | 50.64M | 91.27M | 213.47M | 152.55M | 148.96M | 137.51M | 197.87M | 121.66M | 85.12M | 52.39M | 38.80M | 30.10M | 26.90M | 17.30M |
| Cost & Expenses | 1.64B | 1.24B | 925.70M | 718.40M | 561.50M | 414.35M | 292.99M | 162.37M | 113.97M | 64.41M | 52.60M | 51.69M | 43.41M | 47.22M | 50.64M | 91.27M | 213.47M | 152.55M | 148.96M | 137.51M | 197.87M | 121.66M | 85.12M | 50.19M | 36.70M | 28.40M | 25.60M | 16.30M |
| Interest Income | 0.00 | 11.20M | 3.80M | 12.60M | 19.21M | 0.00 | 0.00 | 2.84M | 1.93M | 629.00K | 400.00K | 489.00K | 435.00K | 397.00K | 691.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 4.60M | 7.10M | 25.80M | 32.80M | 32.00M | 30.53M | 19.52M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.03M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 21.30M | 15.60M | 10.90M | 8.60M | 7.45M | 4.02M | 2.40M | 1.50M | 1.01M | 827.00K | 671.00K | 657.00K | 694.00K | 1.44M | 3.18M | 7.61M | 9.40M | 10.57M | 10.09M | 7.08M | 3.69M | 3.10M | 2.65M | 2.20M | 2.10M | 1.70M | 1.30M | 1.00M |
| EBITDA | 358.00M | 264.60M | 218.70M | 336.10M | 226.60M | 56.40M | -120.62M | -139.59M | -87.92M | -63.58M | -49.01M | 2.11M | 34.62M | -13.72M | -47.86M | -73.98M | -193.97M | -102.75M | -14.98M | -45.25M | -55.10M | -100.52M | -41.23M | -33.40M | -17.80M | -10.70M | 1.80M | 3.90M |
| EBITDA Ratio | 18.97% | 16.73% | 18.33% | 31.31% | 28.75% | 8.18% | -81.29% | -1,024.27% | -503.13% | 0.00% | -1,824.25% | -3.98% | 39.32% | -36.67% | -1,501.32% | -1,650.74% | -8,891.99% | -261.89% | -12.09% | -52.97% | -52.62% | -558.23% | -101.02% | -236.15% | -107.14% | -20.63% | -11.88% | 2.60% |
| Operating Income | 250.90M | 249.00M | 196.90M | 318.90M | 219.15M | 36.90M | -131.36M | -147.37M | -94.20M | -64.41M | -49.68M | 1.45M | 33.92M | -13.72M | -53.67M | -87.30M | -212.24M | -113.32M | -25.07M | -52.33M | -58.79M | -103.62M | -43.88M | -35.60M | -19.90M | -12.40M | 500.00K | 2.90M |
| Operating Income Ratio | 13.30% | 16.73% | 17.37% | 30.49% | 27.81% | 8.18% | -81.27% | -982.48% | -476.51% | 0.00% | -1,701.88% | 2.72% | 43.82% | -40.96% | -1,817.47% | -2,196.18% | -17,340.03% | -288.82% | -20.24% | -61.44% | -42.27% | -574.20% | -106.40% | -244.04% | -118.45% | -77.50% | 1.92% | 15.10% |
| Total Other Income/Expenses | 81.20M | -35.10M | -1.10M | -56.30M | -25.80M | -15.05M | -11.18M | 6.28M | 5.27M | 3.87M | 3.59M | 3.58M | 3.65M | 5.75M | 2.63M | -1.32M | 4.94M | 6.11M | 2.88M | 6.64M | 28.69M | 9.08M | 7.09M | 7.10M | 200.00K | -7.40M | 4.80M | 3.20M |
| Income Before Tax | 332.10M | 213.90M | 101.40M | 106.70M | 46.50M | 21.84M | -142.54M | -141.09M | -88.93M | -60.54M | -46.09M | 5.03M | 37.57M | -7.97M | -88.61M | -88.61M | -207.30M | -107.21M | -22.19M | -45.69M | -30.10M | -94.54M | -36.79M | -28.51M | -19.70M | -19.80M | 5.30M | 6.10M |
| Income Before Tax Ratio | 17.60% | 14.37% | 8.95% | 10.20% | 5.90% | 4.84% | -88.19% | -940.60% | -449.84% | 0.00% | -1,578.97% | 9.46% | 48.53% | -23.78% | -3,000.78% | -2,229.26% | -16,936.19% | -273.25% | -17.91% | -53.65% | -21.64% | -523.89% | -89.21% | -195.41% | -117.26% | -123.75% | 20.31% | 31.77% |
| Income Tax Expense | 82.40M | 59.40M | 11.80M | -300.60M | 9.50M | 730.00K | 17.10M | -7.72M | -6.27M | -4.68M | -4.24M | -4.22M | -4.26M | 0.00 | 173.00K | 1.32M | -4.94M | 0.00 | 0.00 | 79.00K | 158.00K | -9.08M | 120.00K | 302.00K | -3.10M | 7.60M | 200.00K | 200.00K |
| Net Income | 249.70M | 154.50M | 89.60M | 407.30M | 37.00M | 21.11M | -142.54M | -141.09M | -88.93M | -60.54M | -46.09M | 5.03M | 37.57M | -7.97M | -51.04M | -88.61M | -207.30M | -107.21M | -22.19M | -45.77M | -30.26M | -94.54M | -36.91M | -28.81M | -16.80M | -20.00M | 5.10M | 5.90M |
| Net Income Ratio | 13.23% | 10.38% | 7.90% | 38.94% | 4.69% | 4.68% | -88.19% | -940.60% | -449.84% | 0.00% | -1,578.97% | 9.46% | 48.53% | -23.78% | -1,728.34% | -2,229.26% | -16,936.19% | -273.25% | -17.91% | -53.74% | -21.75% | -523.89% | -89.50% | -197.48% | -100.00% | -125.00% | 19.54% | 30.73% |
| EPS | 2.56 | 1.61 | 0.95 | 4.37 | 0.40 | 0.22 | -1.62 | -1.63 | -1.05 | -0.81 | -0.69 | 0.08 | 0.68 | -0.15 | -1.30 | -2.30 | -5.45 | -2.84 | -0.60 | -1.26 | -0.93 | -3.10 | -1.42 | -1.30 | -0.88 | -1.10 | 0.30 | 0.39 |
| EPS Diluted | 2.47 | 1.56 | 0.92 | 4.16 | 0.39 | 0.22 | -1.62 | -1.63 | -1.05 | -0.81 | -0.69 | 0.08 | 0.67 | -0.15 | -1.30 | -2.30 | -5.45 | -2.84 | -0.58 | -1.26 | -0.93 | -3.10 | -1.42 | -1.30 | -0.88 | -1.10 | 0.28 | 0.36 |
| Weighted Avg Shares Out | 97.70M | 95.80M | 94.60M | 93.10M | 91.63M | 95.40M | 87.99M | 86.56M | 84.50M | 74.58M | 66.80M | 65.62M | 55.18M | 52.82M | 39.14M | 38.45M | 38.01M | 37.72M | 36.76M | 36.20M | 32.37M | 30.49M | 26.03M | 22.12M | 19.07M | 18.14M | 17.00M | 15.13M |
| Weighted Avg Shares Out (Dil) | 101.00M | 98.90M | 97.90M | 97.80M | 95.73M | 95.40M | 88.09M | 86.71M | 84.50M | 74.58M | 66.99M | 66.95M | 56.35M | 52.82M | 39.14M | 38.45M | 38.01M | 37.72M | 37.99M | 36.20M | 32.37M | 30.49M | 26.03M | 22.12M | 19.07M | 18.14M | 18.21M | 16.39M |
3 Cutting-Edge Biotech Stocks Sitting on the Brink of Success
PRISM MarketView Highlights Work of Emerging Companies on Rare Disease Day
Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside
Neurocrine Biosciences (NBIX) Q4 2023 Earnings Call Transcript
Neurocrine (NBIX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024
Ahead of Neurocrine (NBIX) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
AMLX vs. NBIX: Which Stock Should Value Investors Buy Now?
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2023 Financial Results
Source: https://incomestatements.info
Category: Stock Reports